Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School
More than 1,400 participants across 65+ countries underscores accelerating adoption of model-informed workflows and growing demand for applied modeling expertise
Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the successful completion of its 2026 Spring School, a global training initiative designed to expand access to model-informed drug development (MIDD) and strengthen the scientific foundation of the industry's future workforce.
More than 1,400 scientists from industry, academia, and regulatory agencies from over 65 countries participated in the week-long program, reflecting the high demand for expert-led training as modeling and simulation increasingly become standard for drug development strategy, regulatory engagement, and clinical execution.
"As model-informed approaches become central to how therapies are developed, it is vital to apply modeling and simulation consistently across teams," said Jonathan Chauvin, Co-Chief Product and Technology Officer of Simulations Plus. "Through programs like Spring School, we are expanding access to these capabilities to support the next generation of scientists, while enabling broader adoption of model-informed workflows across the industry. These foundational skills are essential for scientists to evolve with the discipline and leverage validated scientific engines and AI-enabled ecosystems to support better decision-making across the drug development lifecycle."
Held from March 23 to 27, 2026, the Spring School program offered two tracks: GastroPlus® Spring School: From PBPK Basics to Biopharmaceutics Applications, and MonolixSuite™ Spring School: High-Impact Pharmacometrics Case Studies. Both tracks included interactive lectures, hands-on exercises, and live Q&A sessions led by Simulations Plus experts.
"The continued scale and diversity of participation in this year's program reflects how quickly model-informed approaches are becoming embedded across the global scientific community," said Jennifer Johnson, Manager of Learning Services of Simulations Plus. "Our focus is on building programs that not only educate but also help scientists translate these methods into real-world workflows and collaborative environments."
Simulations Plus has a long-standing commitment to education. In addition to its Spring School, the Company has previously offered Summer and Autumn Schools focused on PK/PD modeling. The most recent Autumn School was the first program to offer a second track focused on PBPK modeling. In addition to these programs, Simulations Plus is widely known for its University+ program, which provides free academic access to modeling and simulation software for thousands of students and educators worldwide. Together, these initiatives form a cornerstone of the Company's global educational outreach—helping expand the adoption of model-informed approaches and strengthening the pipeline of scientists equipped to apply these methods across the drug development lifecycle.
About Simulations Plus, Inc.
Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions. For more information, visit www.simulations-plus.com.
Forward-Looking Statements
Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "will", "can", "believe", "expect," "anticipate" and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new operational structure, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260420146742/en/
Financial Profiles
Lisa Fortuna
310-622-8251
[email protected]